VALNEVA SE - ADR (VALN) Fundamental Analysis & Valuation

NASDAQ:VALN • US92025Y1038

11.11 USD
+0.14 (+1.28%)
Last: Mar 5, 2026, 08:25 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This VALN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

VALN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 520 industry peers in the Biotechnology industry. VALN has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, VALN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

2

1. VALN Profitability Analysis

1.1 Basic Checks

  • VALN had negative earnings in the past year.
  • VALN had a negative operating cash flow in the past year.
  • VALN had negative earnings in each of the past 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: VALN reported negative operating cash flow in multiple years.
VALN Yearly Net Income VS EBIT VS OCF VS FCFVALN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -26.86%, VALN is in the better half of the industry, outperforming 68.27% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -80.02%, VALN is in line with its industry, outperforming 51.54% of the companies in the same industry.
Industry RankSector Rank
ROA -26.86%
ROE -80.02%
ROIC N/A
ROA(3y)-15.85%
ROA(5y)-14.17%
ROE(3y)-50.34%
ROE(5y)-55.45%
ROIC(3y)N/A
ROIC(5y)N/A
VALN Yearly ROA, ROE, ROICVALN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

  • With a decent Gross Margin value of 46.53%, VALN is doing good in the industry, outperforming 74.81% of the companies in the same industry.
  • VALN's Gross Margin has declined in the last couple of years.
  • VALN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 46.53%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.2%
GM growth 5Y-7.06%
VALN Yearly Profit, Operating, Gross MarginsVALN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 -60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. VALN Health Analysis

2.1 Basic Checks

  • VALN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, VALN has more shares outstanding
  • VALN has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, VALN has an improved debt to assets ratio.
VALN Yearly Shares OutstandingVALN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
VALN Yearly Total Debt VS Total AssetsVALN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • Based on the Altman-Z score of 0.18, we must say that VALN is in the distress zone and has some risk of bankruptcy.
  • VALN's Altman-Z score of 0.18 is in line compared to the rest of the industry. VALN outperforms 60.00% of its industry peers.
  • A Debt/Equity ratio of 0.89 indicates that VALN is somewhat dependend on debt financing.
  • VALN has a Debt to Equity ratio of 0.89. This is in the lower half of the industry: VALN underperforms 73.46% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.89
Debt/FCF N/A
Altman-Z 0.18
ROIC/WACCN/A
WACC8.03%
VALN Yearly LT Debt VS Equity VS FCFVALN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

2.3 Liquidity

  • VALN has a Current Ratio of 1.78. This is a normal value and indicates that VALN is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.78, VALN is doing worse than 78.27% of the companies in the same industry.
  • VALN has a Quick Ratio of 1.36. This is a normal value and indicates that VALN is financially healthy and should not expect problems in meeting its short term obligations.
  • VALN has a Quick ratio of 1.36. This is amonst the worse of the industry: VALN underperforms 81.92% of its industry peers.
Industry RankSector Rank
Current Ratio 1.78
Quick Ratio 1.36
VALN Yearly Current Assets VS Current LiabilitesVALN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. VALN Growth Analysis

3.1 Past

  • VALN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1180.00%.
  • VALN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.89%.
  • VALN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.09% yearly.
EPS 1Y (TTM)-1180%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-271.43%
Revenue 1Y (TTM)19.89%
Revenue growth 3Y-21.31%
Revenue growth 5Y6.09%
Sales Q2Q%-35.76%

3.2 Future

  • VALN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 54.65% yearly.
  • The Revenue is expected to grow by 14.73% on average over the next years. This is quite good.
EPS Next Y-607%
EPS Next 2Y-121.49%
EPS Next 3Y101.1%
EPS Next 5Y54.65%
Revenue Next Year-8.51%
Revenue Next 2Y-1.76%
Revenue Next 3Y22.87%
Revenue Next 5Y14.73%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VALN Yearly Revenue VS EstimatesVALN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M
VALN Yearly EPS VS EstimatesVALN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 1 -1 2 -2

More info and screens

Find the best growth stocksShow best growing peers

1

4. VALN Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for VALN. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VALN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VALN Price Earnings VS Forward Price EarningsVALN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VALN Per share dataVALN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

  • VALN's earnings are expected to grow with 101.09% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-121.49%
EPS Next 3Y101.1%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VALN Dividend Analysis

5.1 Amount

  • VALN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VALN Fundamentals: All Metrics, Ratios and Statistics

VALNEVA SE - ADR

NASDAQ:VALN (3/5/2026, 8:25:18 PM)

11.11

+0.14 (+1.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-20
Earnings (Next)03-19
Inst Owners24.02%
Inst Owner Change-0.87%
Ins Owners0.21%
Ins Owner ChangeN/A
Market Cap963.32M
Revenue(TTM)274.97M
Net Income(TTM)-120.41M
Analysts81.82
Price Target17.37 (56.35%)
Short Float %0.18%
Short Ratio7.15
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-17%
Min EPS beat(2)-90.69%
Max EPS beat(2)56.68%
EPS beat(4)2
Avg EPS beat(4)-21.59%
Min EPS beat(4)-115.24%
Max EPS beat(4)62.87%
EPS beat(8)4
Avg EPS beat(8)-5.97%
EPS beat(12)6
Avg EPS beat(12)-29.73%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-5.23%
Min Revenue beat(2)-26.86%
Max Revenue beat(2)16.4%
Revenue beat(4)2
Avg Revenue beat(4)2.94%
Min Revenue beat(4)-26.86%
Max Revenue beat(4)26.97%
Revenue beat(8)3
Avg Revenue beat(8)-2.55%
Revenue beat(12)7
Avg Revenue beat(12)17.96%
Revenue beat(16)9
Avg Revenue beat(16)99.55%
PT rev (1m)3.11%
PT rev (3m)3.53%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-20.65%
EPS NY rev (1m)0%
EPS NY rev (3m)-10.1%
Revenue NQ rev (1m)-0.04%
Revenue NQ rev (3m)-12.06%
Revenue NY rev (1m)-1.95%
Revenue NY rev (3m)-4.9%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.01
P/FCF N/A
P/OCF N/A
P/B 5.5
P/tB 6.49
EV/EBITDA N/A
EPS(TTM)-1.56
EYN/A
EPS(NY)-0.84
Fwd EYN/A
FCF(TTM)-0.24
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS3.69
BVpS2.02
TBVpS1.71
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -26.86%
ROE -80.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 46.53%
FCFM N/A
ROA(3y)-15.85%
ROA(5y)-14.17%
ROE(3y)-50.34%
ROE(5y)-55.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.2%
GM growth 5Y-7.06%
F-Score4
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0.89
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.08%
Cap/Sales 0.22%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.78
Quick Ratio 1.36
Altman-Z 0.18
F-Score4
WACC8.03%
ROIC/WACCN/A
Cap/Depr(3y)101.58%
Cap/Depr(5y)231.17%
Cap/Sales(3y)9.04%
Cap/Sales(5y)14.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1180%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-271.43%
EPS Next Y-607%
EPS Next 2Y-121.49%
EPS Next 3Y101.1%
EPS Next 5Y54.65%
Revenue 1Y (TTM)19.89%
Revenue growth 3Y-21.31%
Revenue growth 5Y6.09%
Sales Q2Q%-35.76%
Revenue Next Year-8.51%
Revenue Next 2Y-1.76%
Revenue Next 3Y22.87%
Revenue Next 5Y14.73%
EBIT growth 1Y-162.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-276.1%
EBIT Next 3Y54.49%
EBIT Next 5Y7.2%
FCF growth 1Y91.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y90.46%
OCF growth 3YN/A
OCF growth 5YN/A

VALNEVA SE - ADR / VALN FAQ

What is the fundamental rating for VALN stock?

ChartMill assigns a fundamental rating of 2 / 10 to VALN.


What is the valuation status for VALN stock?

ChartMill assigns a valuation rating of 1 / 10 to VALNEVA SE - ADR (VALN). This can be considered as Overvalued.


What is the profitability of VALN stock?

VALNEVA SE - ADR (VALN) has a profitability rating of 2 / 10.


How financially healthy is VALNEVA SE - ADR?

The financial health rating of VALNEVA SE - ADR (VALN) is 2 / 10.